Compare Hims and Hers Health Inc (HIMS) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Linde PLC — how do they compare? Hims and Hers Health Inc trades at $29.32 (market cap $6.55B), while Linde PLC trades at $483.75 (market cap $222.05B). The key difference: Linde PLC is far larger — about 33.9× Hims and Hers Health Inc's market cap, and Linde PLC pays a 1.33% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Linde PLC for 88 Days on average.
| HIMS | LIN | |
|---|---|---|
Market Cap | $6.55B | $222.05B |
Volume | 14,842,814 | 2,116,440 |
Sector | Health | Basic Materials |
52-Week High | $62.76 | $546.64 |
52-Week Low | $14.52 | $389.38 |
Typical Hold Time | 21 Days | 88 Days |
Enterprise Value | $7.25B | $245.17B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
LIN trades at $483.98, down 1.22% on the day, with a bullish technical signal from moving averages and strong support near $482. The company reported record Q2 2026 EPS of $4.50, beating estimates, and maintains robust profitability with a 20.43% net income margin. Revenue growth is steady, projected at $35.4B for 2026, while valuation multiples like the 31.08 P/E reflect premium pricing. Analyst sentiment is overwhelmingly positive, with 89.66% buy ratings and a $557.10 consensus price target, citing LIN's role in AI chip supply chains.
The outlook for LIN is favorable, driven by earnings beats, a record $8.1B project backlog, and strategic positioning in high-growth sectors like electronics. Key risks include elevated valuation requiring sustained growth, rising debt-to-asset ratios, and margin pressures from increased capital expenditure. Investors should weigh the company's strong execution against potential sector-wide competition and macroeconomic headwinds affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
